Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
Abstract
Increased generation of reactive oxygen species (ROS) and an altered redox status have long been observed in cancer cells, and recent studies suggest that this biochemical property of cancer cells can be exploited for therapeutic benefits. Cancer cells in advanced stage tumours frequently exhibit multiple genetic alterations and high oxidative stress, suggesting that it might be possible to preferentially eliminate these cells by pharmacological ROS insults. However, the upregulation of antioxidant capacity in adaptation to intrinsic oxidative stress in cancer cells can confer drug resistance. Abrogation of such drug-resistant mechanisms by redox modulation could have significant therapeutic implications. We argue that modulating the unique redox regulatory mechanisms of cancer cells might be an effective strategy to eliminate these cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, available data suggest that MGF-driven restoration of redox homeostasis represents a central mechanistic axis of its antitumor activity, rather than merely a downstream branch of apoptosis (84,85).”
From Mangiferin in human disease: Multifaceted mechanisms and applications (Review) (2026) · cites this paper as [84]
In the citing paper
“Activation of oncogenes, aberrant metabolism, mitochondrial dysfunction, and loss of the tumor suppressor p53 can all promote increased ROS accumulation in cancer cells 69.”
From Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes (2010) · cites this paper as [69]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379 · cited 1×
“It has been observed that a small subpopulation of primary cancer cells expressing stem-cell markers was resistant to certain chemotherapeutic agents and radiatio”
BackgroundSchafer, F. Q., & Buettner, G. R. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00480-4 · Cited by 4,587 · cited 1×
“A moderate increase in ROS can promote cell proliferation and differentiatio”
BackgroundFive-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488 · cited 1×
“By exploiting the genetic differences between normal cells and cancer cells, several molecular-targeted drugs, such as imatinib (Gleevec; Novartis) and trastuzumab (Herceptin; Genentech/Roche), show promising therapeutic activity and few toxic side effect”
BackgroundCancer stem cells in solid tumours: accumulating evidence and unresolved questions
Visvader, J. E., & Lindeman, G. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2499 · Cited by 3,429 · cited 1×
“Redox status in cancer stem cells Recurrence of cancer after chemotherapy or radiotherapy is initiated by a subpopulation of residual malignant cells that are highly resistant to treatment and which are believed to be cancer-initiating cells or cancer stem cell”
Background(2012) · Hepatogastroenterology · doi:10.5754/hge12469 · Cited by 3,178
Production of large amounts of hydrogen peroxide by human tumor cells.
Szatrowski, T. P., & Nathan, C. (1991) · PubMed · Cited by 3,007
Association of reactive oxygen species levels and radioresistance in cancer stem cells
Diehn, M., Cho, R. W., Lobo, N. A., Kalisky, T., Dorie, M. J., Kulp, A. N., Qian, D., Lam, J. S., Ailles, L. E., Wong, M., et al. (2009) · Nature · doi:10.1038/nature07733 · Cited by 2,555 · cited 1×
“Recent studies showed that normal haemopoietic stem cells and normal mammary epithelial stem cells maintained ROS at lower levels than their mature progeny to prevent cellular differentiation and maintain long-term self-renewa”
BackgroundBjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2007) · JAMA · doi:10.1001/jama.297.8.842 · Cited by 2,275
Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,272 · cited 1×
“This is consistent with the high incidence of p53 mutation or loss of p53 function in over 50% of human cancer”
BackgroundROS stress in cancer cells and therapeutic implications
Pelicano, H., Carney, D., & Huang, P. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.01.004 · Cited by 2,006 · cited 1×
“However, as excessive levels of ROS stress can also be toxic to the cells, cancer cells with increased oxidative stress are likely to be more vulnerable to damage by further ROS insults induced by exogenous agent”
BackgroundSelf-citationIntrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy
Li, X., Lewis, M. T., Huang, J., Gutierrez, C., Osborne, C. K., Wu, M.-F., Hilsenbeck, S. G., Pavlick, A., Zhang, X., Chamness, G. C., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn123 · Cited by 1,794 · cited 1×
“It has been observed that a small subpopulation of primary cancer cells expressing stem-cell markers was resistant to certain chemotherapeutic agents and radiatio”
BackgroundRedox regulation of cell survival
Trachootham, D., Lu, W., Ogasawara, M. A., Valle, N. R.-D., & Huang, P. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1957 · Cited by 1,781 · cited 1×
“ROS can modulate the activities and expression of many transcription factors and signalling proteins that are involved in the stress response and cell survival through multiple mechanism”
BackgroundSelf-citationGriffith, O. W., & Meister, A. (1979) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35980-5 · Cited by 1,683
Mitogenic Signaling Mediated by Oxidants in Ras-Transformed Fibroblasts
Irani, K., Xia, Y., Zweier, J. L., Sollott, S. J., Der, C. J., Fearon, E. R., Sundaresan, M., Finkel, T., & Goldschmidt-Clermont, P. J. (1997) · Science · doi:10.1126/science.275.5306.1649 · Cited by 1,588
FoxOs Are Critical Mediators of Hematopoietic Stem Cell Resistance to Physiologic Oxidative Stress
Tothova, Z., Kollipara, R., Huntly, B. J., Lee, B. H., Castrillon, D. H., Cullen, D. E., McDowell, E. P., Lazo-Kallanian, S., Williams, I. R., Sears, C., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.003 · Cited by 1,562 · cited 1×
“The transcription factor Forkhead Box Os (FoxOs) was identified as a crucial factor to upregulate the expression of SOD and catalase, which confer resistance to oxidative stress and maintain stemness in this cell populatio”
BackgroundROS-Generating Mitochondrial DNA Mutations Can Regulate Tumor Cell Metastasis
Ishikawa, K., Takenaga, K., Akimoto, M., Koshikawa, N., Yamaguchi, A., Imanishi, H., Nakada, K., Honma, Y., & Hayashi, J.-I. (2008) · Science · doi:10.1126/science.1156906 · Cited by 1,444 · cited 1×
“Besides oncogenic transformation, mitochondrial DNA (mtDNA) mutations have also been shown to be correlated with increased ROS levels in certain types of cancer cell, including those in solid tumours and leukaemi”
BackgroundThe role of glutathione-S-transferase in anti-cancer drug resistance
Townsend, D. M., & Tew, K. D. (2003) · Oncogene · doi:10.1038/sj.onc.1206940 · Cited by 1,353
The Response of CD24 −/low /CD44 + Breast Cancer–Initiating Cells to Radiation
Phillips, T. M., McBride, W. H., & Pajonk, F. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj495 · Cited by 1,309
Oxidative stress and cancer: Have we moved forward?
Halliwell, B. (2007) · Biochemical Journal · doi:10.1042/bj20061131 · Cited by 1,302 · cited 1×
“Although in some studies the observed increase of oxidative stress might be due to sample handling, analytical artefacts or cell-culture condition”
BackgroundRac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability
Radisky, D. C., Levy, D. D., Littlepage, L. E., Liu, H., Nelson, C. M., Fata, J. E., Leake, D., Godden, E. L., Albertson, D. G., Angela Nieto, M., et al. (2005) · Nature · doi:10.1038/nature03688 · Cited by 1,284
Reactive oxygen species in cancer cells: Live by the sword, die by the sword
Schumacker, P. T. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.015 · Cited by 1,242 · cited 1×
“Therefore, manipulating ROS levels by redox modulation is a way to selectively kill cancer cells without causing significant toxicity to normal cell”
BackgroundPersistent oxidative stress in cancer
Toyokuni, S., Okamoto, K., Yodoi, J., & Hiai, H. (1995) · FEBS Letters · doi:10.1016/0014-5793(94)01368-b · Cited by 1,219 · cited 1×
“Mounting evidence suggests that, compared with their normal counterparts, many types of cancer cell have increased levels of reactive oxygen species (ROS”
BackgroundComplete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide
Soignet, S. L., Maslak, P., Wang, Z.-G., Jhanwar, S., Calleja, E., Dardashti, L. J., Corso, D., DeBlasio, A., Gabrilove, J., Scheinberg, D. A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391901 · Cited by 1,213
Giorgio, M., Migliaccio, E., Orsini, F., Paolucci, D., Moroni, M., Contursi, C., Pelliccia, G., Luzi, L., Minucci, S., Marcaccio, M., et al. (2005) · Cell · doi:10.1016/j.cell.2005.05.011 · Cited by 1,176 · cited 1×
“Furthermore, p53 also acts as a transcription factor to regulate the expression of many pro-oxidant and antioxidant gene”
BackgroundRegulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells
Ito, K., Hirao, A., Arai, F., Matsuoka, S., Takubo, K., Hamaguchi, I., Nomiyama, K., Hosokawa, K., Sakurada, K., Nakagata, N., et al. (2004) · Nature · doi:10.1038/nature02989 · Cited by 1,175 · cited 1×
“Recent studies showed that normal haemopoietic stem cells and normal mammary epithelial stem cells maintained ROS at lower levels than their mature progeny to prevent cellular differentiation and maintain long-term self-renewa”
BackgroundThe antioxidant function of the p53 tumor suppressor
Sablina, A. A., Budanov, A. V., Ilyinskaya, G. V., Agapova, L. S., Kravchenko, J. E., & Chumakov, P. M. (2005) · Nature Medicine · doi:10.1038/nm1320 · Cited by 1,121 · cited 1×
“Furthermore, p53 also acts as a transcription factor to regulate the expression of many pro-oxidant and antioxidant gene”
BackgroundAdriamycin: The Role of Lipid Peroxidation in Cardiac Toxicity and Tumor Response
Myers, C. E., McGuire, W. P., Liss, R. H., Ifrim, I., Grotzinger, K., & Young, R. C. (1977) · Science · doi:10.1126/science.877547 · Cited by 1,111
Role of superoxide dismutase in cancer: a review.
Oberley, L. W., & Buettner, G. R. (1979) · PubMed · Cited by 1,102
Trachootham, D., Zhou, Y., Zhang, H., Demizu, Y., Chen, Z., Pelicano, H., Chiao, P. J., Achanta, G., Arlinghaus, R. B., Liu, J., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.009 · Cited by 1,080
Self-citationThe role of oxygen availability in embryonic development and stem cell function
Simon, M. C., & Keith, B. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2354 · Cited by 967 · cited 1×
“These hypoxic niches may have a role in limiting differentiation and maintaining stemnes”
BackgroundReactive Oxygen Species: A Breath of Life or Death?
Fruehauf, J. P., & Meyskens, F. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2082 · Cited by 915
Jang, Y.-Y., & Sharkis, S. J. (2007) · Blood · doi:10.1182/blood-2007-05-087759 · Cited by 894 · cited 1×
“Recent studies showed that normal haemopoietic stem cells and normal mammary epithelial stem cells maintained ROS at lower levels than their mature progeny to prevent cellular differentiation and maintain long-term self-renewa”
Backgroundc-Myc Can Induce DNA Damage, Increase Reactive Oxygen Species, and Mitigate p53 Function
Vafa, O., Wade, M., Kern, S., Beeche, M., Pandita, T. K., Hampton, G. M., & Wahl, G. M. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00520-8 · Cited by 876
Superoxide dismutase as a target for the selective killing of cancer cells
Huang, P., Feng, L., Oldham, E. A., Keating, M. J., & Plunkett, W. (2000) · Nature · doi:10.1038/35030140 · Cited by 842 · cited 1×
“Examples of SOD inhibitors include certain oestrogen derivatives such as 2-methoxyestradiol (2-ME”
BackgroundSelf-citationMitochondrial mutations in cancer
Brandon, M., Baldi, P., & Wallace, D. C. (2006) · Oncogene · doi:10.1038/sj.onc.1209607 · Cited by 818
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Comoglio, P. M., Giordano, S., & Trusolino, L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2530 · Cited by 818 · cited 1×
“By exploiting the genetic differences between normal cells and cancer cells, several molecular-targeted drugs, such as imatinib (Gleevec; Novartis) and trastuzumab (Herceptin; Genentech/Roche), show promising therapeutic activity and few toxic side effect”
BackgroundCancer cell killing via ROS: To increase or decrease, that is the question
Wang, J., & Yi, J. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.12.7067 · Cited by 790
The signaling mechanism of ROS in tumor progression
Wu, W.-S. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9037-8 · Cited by 752 · cited 1×
“Because the increase of ROS in cancer cells may play an important part in the initiation and progression of cance”
BackgroundBoonstra, J., & Post, J. A. (2004) · Gene · doi:10.1016/j.gene.2004.04.032 · Cited by 737 · cited 1×
“A moderate increase in ROS can promote cell proliferation and differentiatio”
BackgroundSurvival of the Fittest: Cancer Stem Cells in Therapeutic Resistance and Angiogenesis
Eyler, C. E., & Rich, J. N. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.1829 · Cited by 737
Oxidative Stress Is Inherent in Prostate Cancer Cells and Is Required for Aggressive Phenotype
Kumar, B., Koul, S., Khandrika, L., Meacham, R. B., & Koul, H. K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5259 · Cited by 736 · cited 1×
“In solid tumours, studies have shown increased levels of oxidative damage products, such as oxidized DNA base (8OHdG), and lipid peroxidation products in clinical tumour specimens, plasma and cancer cell line”
BackgroundElchuri, S., Oberley, T. D., Qi, W., Eisenstein, R. S., Jackson Roberts, L., Van Remmen, H., Epstein, C. J., & Huang, T.-T. (2005) · Oncogene · doi:10.1038/sj.onc.1208207 · Cited by 667 · cited 1×
“Animal studies using either gene knockout or transgenic overexpression approaches demonstrated a potential role for antioxidant molecules, such as SOD, glutathione peroxidases and peroxiredoxin as tumour suppressor”
BackgroundHalliwell, B. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02075-4 · Cited by 655
Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy
Ushio-Fukai, M., & Nakamura, Y. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.02.044 · Cited by 651
Niu, C., Yan, H., Yu, T., Sun, H.-P., Liu, J.-X., Li, X.-S., Wu, W., Zhang, F.-Q., Chen, Y., Zhou, L., et al. (1999) · Blood · doi:10.1182/blood.v94.10.3315.422k16_3315_3324 · Cited by 625
Bioenergetics and the formation of mitochondrial reactive oxygen species
Adam-Vizi, V., & Chinopoulos, C. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.10.005 · Cited by 610 · cited 1×
“Electrons leaked from the respiratory complexes in mitochondria are a major source for ROS productio”
BackgroundReactive oxygen species in oncogenic transformation
Behrend, L., Henderson, G., & Zwacka, R. M. (2003) · Biochemical Society Transactions · doi:10.1042/bst0311441 · Cited by 531 · cited 1×
“Because the increase of ROS in cancer cells may play an important part in the initiation and progression of cance”
BackgroundIndo, H. P., Davidson, M., Yen, H.-C., Suenaga, S., Tomita, K., Nishii, T., Higuchi, M., Koga, Y., Ozawa, T., & Majima, H. J. (2007) · Mitochondrion · doi:10.1016/j.mito.2006.11.026 · Cited by 530 · cited 1×
“Besides oncogenic transformation, mitochondrial DNA (mtDNA) mutations have also been shown to be correlated with increased ROS levels in certain types of cancer cell, including those in solid tumours and leukaemi”
BackgroundTakahashi, A., Ohtani, N., Yamakoshi, K., Iida, S.-I., Tahara, H., Nakayama, K., Nakayama, K. I., Ide, T., Saya, H., & Hara, E. (2006) · Nature Cell Biology · doi:10.1038/ncb1491 · Cited by 528
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide
Lu, J., Chew, E.-H., & Holmgren, A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701549104 · Cited by 526
Coping with stress: multiple ways to activate p53
Horn, H. F., & Vousden, K. H. (2007) · Oncogene · doi:10.1038/sj.onc.1210263 · Cited by 522
Whitnall, M., Howard, J., Ponka, P., & Richardson, D. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604979103 · Cited by 509 · cited 1×
“Other iron chelators that have been developed to alter ROS production are Dp44m”
BackgroundXia, C., Meng, Q., Liu, L.-Z., Rojanasakul, Y., Wang, X.-R., & Jiang, B.-H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0783 · Cited by 507 · cited 1×
“For example, recent work showed that cancer cells may respond to ROS stress by increasing their levels of vascular endothelial growth factor ( VEGF ), which induces angiogenesis, and by activating the transcription factor HIF-1, leading to enhanced glycolysis, which suppresses cellular senescenc”
BackgroundInhibition of Mitochondrial Respiration
Pelicano, H., Feng, L., Zhou, Y., Carew, J. S., Hileman, E. O., Plunkett, W., Keating, M. J., & Huang, P. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301546200 · Cited by 495
Self-citationAnticarcinogenic activities of organic isothiocyanates: chemistry and mechanisms.
Zhang, Y., & Talalay, P. (1994) · PubMed · Cited by 478
Role of mitochondrial DNA in toxic responses to oxidative stress
Van Houten, B., Woshner, V., & Santos, J. H. (2006) · DNA Repair · doi:10.1016/j.dnarep.2005.03.002 · Cited by 454 · cited 1×
“At an advanced disease stage, cancer cells usually exhibit genetic instability and show a significant increase in ROS generation, due in part to a 'vicious cycle', in which ROS induce gene mutations (especially in the mitochondrial genome) leading to further metabolic malfunction and ROS generatio”
BackgroundKawanishi, S., Hiraku, Y., Pinlaor, S., & Ma, N. (2006) · Biological Chemistry · doi:10.1515/bc.2006.049 · Cited by 449 · cited 1×
“Mounting evidence suggests that, compared with their normal counterparts, many types of cancer cell have increased levels of reactive oxygen species (ROS”
BackgroundInflammation and Lung Cancer: Roles of Reactive Oxygen/Nitrogen Species
Azad, N., Rojanasakul, Y., & Vallyathan, V. (2008) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937400701436460 · Cited by 409
The x cystine/glutamate antiporter: A potential target for therapy of cancer and other diseases
Lo, M., Wang, Y., & Gout, P. W. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21366 · Cited by 399 · cited 1×
“Furthermore, inhibitors of the x C − cystine/glutamate antiporter, such as sulphasalazine, may also cause GSH depletion by inhibiting the uptake of cystine, the precursor of cysteine, which is a rate-limiting substrate for GSH synthesi”
BackgroundReactive oxygen species in tumor metastasis
Nishikawa, M. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.02.031 · Cited by 398
Antioxidant enzyme levels in cancer.
Oberley, T. D., & Oberley, L. W. (1997) · PubMed · Cited by 389
Oxidative Stress in the Regulation of Normal and Neoplastic Hematopoiesis
Ghaffari, S. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2142 · Cited by 376
Finch, R. A., Liu, M.-C., Grill, S. P., Rose, W. C., Loomis, R., Vasquez, K. M., Cheng, Y.-C., & Sartorelli, A. C. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00419-0 · Cited by 366
Endothelial Nitric Oxide Synthase-Dependent Superoxide Generation from Adriamycin
Vásquez-Vivar, J., Martasek, P., Hogg, N., Masters, B. S. S., Pritchard, & Kalyanaraman, B. (1997) · Biochemistry · doi:10.1021/bi971475e · Cited by 366
Bey, E. A., Bentle, M. S., Reinicke, K. E., Dong, Y., Yang, C.-R., Girard, L., Minna, J. D., Bornmann, W. G., Gao, J., & Boothman, D. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702176104 · Cited by 354
Elesclomol induces cancer cell apoptosis through oxidative stress
Kirshner, J. R., He, S., Balasubramanyam, V., Kepros, J., Yang, C.-Y., Zhang, M., Du, Z., Barsoum, J., & Bertin, J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0298 · Cited by 353 · cited 1×
“Elesclomol (STA-4783), a novel compound that showed therapeutic activity in malignant melanoma and prolonged the progression-free survival time in a Phase II clinical tria”
BackgroundAdaptation of Energy Metabolism in Breast Cancer Brain Metastases
Chen, E. I., Hewel, J., Krueger, J. S., Tiraby, C., Weber, M. R., Kralli, A., Becker, K., Yates, J. R., & Felding-Habermann, B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3137 · Cited by 352 · cited 1×
“Recent evidence suggests that such adaptation contributes to malignant transformation, metastasis and resistance to anticancer drug”
BackgroundKARIHTALA, P., & SOINI, Y. (2007) · APMIS · doi:10.1111/j.1600-0463.2007.apm_514.x · Cited by 339
Lipid peroxidation, free radical production and antioxidant status in breast cancer
Ray, G., Batra, S., Shukla, N. K., Deo, S., Raina, V., Ashok, S., & Husain, S. A. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006357330486 · Cited by 335 · cited 1×
“Increases in ROS or oxidative DNA and lipid products in some primary cancer cells are associated with a decrease in antioxidants, such as SOD and catalas”
BackgroundZhou, Y., Hileman, E. O., Plunkett, W., Keating, M. J., & Huang, P. (2003) · Blood · doi:10.1182/blood-2002-08-2512 · Cited by 327
Self-citationFrantz, S. (2005) · Nature · doi:10.1038/437942a · Cited by 322
Alexandre, J., Batteux, F., Nicco, C., Chéreau, C., Laurent, A., Guillevin, L., Weill, B., & Goldwasser, F. (2006) · International Journal of Cancer · doi:10.1002/ijc.21685 · Cited by 310
Self-citationHow important is oxidative damage? Lessons from Alzheimer’s disease
Perry, G., Raina, A. K., Nunomura, A., Wataya, T., Sayre, L. M., & Smith, M. A. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00158-1 · Cited by 288 · cited 1×
“, whereas excessive amounts of ROS can cause oxidative damage to lipids, proteins and DN”
BackgroundResistance to Paclitaxel Is Proportional to Cellular Total Antioxidant Capacity
Ramanathan, B., Jan, K.-Y., Chen, C.-H., Hour, T.-C., Yu, H.-J., & Pu, Y.-S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1162 · Cited by 287 · cited 1×
“, low clinical response and resistance to those agents were also reporte”
BackgroundNovel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol γ
Achanta, G., Sasaki, R., Feng, L., Carew, J. S., Lu, W., Pelicano, H., Keating, M. J., & Huang, P. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600819 · Cited by 285
Self-citationOxidative stress, redox, and the tumor microenvironment
Cook, J. A., Gius, D., Wink, D. A., Krishna, M. C., Russo, A., & Mitchell, J. B. (2004) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2004.04.001 · Cited by 284 · cited 1×
“In addition to the internal stimuli, extrinsic factors such as inflammatory cytokines, an imbalance of nutrients and a hypoxic environment could also affect intracellular redox homeostasi”
BackgroundMitochondrial Manganese-Superoxide Dismutase Expression in Ovarian Cancer
Hu, Y., Rosen, D. G., Zhou, Y., Feng, L., Yang, G., Liu, J., & Huang, P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503296200 · Cited by 279
Self-citationLipid peroxidation and antioxidant status in colorectal cancer
Skrzydlewska, E. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i3.403 · Cited by 278
Bairati, I., Meyer, F., Gélinas, M., Fortin, A., Nabid, A., Brochet, F., Mercier, J.-P., Têtu, B., Harel, F., Abdous, B., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.514 · Cited by 261
Juarez, J. C., Manuia, M., Burnett, M. E., Betancourt, O., Boivin, B., Shaw, D. E., Tonks, N. K., Mazar, A. P., & Doñate, F. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709451105 · Cited by 257
A threshold concept for cancer therapy
Kong, Q., Beel, J. A., & Lillehei, K. O. (2000) · Medical Hypotheses · doi:10.1054/mehy.1999.0982 · Cited by 250 · cited 1×
“The idea of inducing preferential cancer cell death by a ROS-mediated mechanism based on the different redox states in normal and malignant cells ( Box 2 ) was proposed a decade ag”
Background(2003) · PubMed · Cited by 250
p53 and its isoforms in cancer
Bourdon, J.-C. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603886 · Cited by 245
Regulation of Reactive Oxygen Species and Genomic Stability in Hematopoietic Stem Cells
Naka, K., Muraguchi, T., Hoshii, T., & Hirao, A. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2114 · Cited by 244 · cited 1×
“The transcription factor Forkhead Box Os (FoxOs) was identified as a crucial factor to upregulate the expression of SOD and catalase, which confer resistance to oxidative stress and maintain stemness in this cell populatio”
BackgroundRamsey, M. R., & Sharpless, N. E. (2006) · Nature Cell Biology · doi:10.1038/ncb1106-1213 · Cited by 237 · cited 1×
“Interestingly, in contrast to the tumour-promoting effect, recent work suggests that the high level of ROS has an unexpected role in inducing and maintaining senescence-induced tumour suppression, through sustained activation of the cell-cycle inhibitor p16 INK4A (Ref”
BackgroundKotamraju, S., Chitambar, C. R., Kalivendi, S. V., Joseph, J., & Kalyanaraman, B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111604200 · Cited by 233 · cited 1×
“Another mechanism of doxorubicin-induced ROS production is the intracellular chelation of iron, which may trigger a Fenton-type reaction leading to the generation of the highly reactive hydroxyl radica”
BackgroundRegulation of reactive oxygen species, DNA damage and c-Myc function by peroxiredoxin 1
Egler, R. A., Fernandes, E., Rothermund, K., Sereika, S., de Souza-Pinto, N., Jaruga, P., Dizdaroglu, M., & Prochownik, E. V. (2005) · Oncogene · doi:10.1038/sj.onc.1208821 · Cited by 231
Mechanisms of ROS modulated cell survival during carcinogenesis
Clerkin, J. S., Naughton, R., Quiney, C., & Cotter, T. G. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.02.029 · Cited by 219 · cited 1×
“; cell survival and disruption of cell death signallin”
Backgroundc-Myc Phosphorylation Is Required for Cellular Response to Oxidative Stress
Benassi, B., Fanciulli, M., Fiorentino, F., Porrello, A., Chiorino, G., Loda, M., Zupi, G., & Biroccio, A. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.009 · Cited by 207 · cited 1×
“Apoptosis induced by downregulation of c-Myc was associated with cellular depletion of reduced GS”
BackgroundEffective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism
Trachootham, D., Zhang, H., Zhang, W., Feng, L., Du, M., Zhou, Y., Chen, Z., Pelicano, H., Plunkett, W., Wierda, W. G., et al. (2008) · Blood · doi:10.1182/blood-2008-04-149815 · Cited by 203 · cited 1×
“Recent studies demonstrated that rapid depletion of GSH using the natural compound PEITC, can preferentially kill the Ras -transformed ovarian cells and primary leukaemia cells from patients, and effectively eliminate the drug-resistant cell population”
BackgroundSelf-citationOxidative stress and apoptosis: a new treatment paradigm in cancer
Engel, R. (2006) · Frontiers in Bioscience · doi:10.2741/1798 · Cited by 202
Wallace, D. C. (2005) · Gene · doi:10.1016/j.gene.2005.05.001 · Cited by 199 · cited 1×
“This genomic instability allows 'silent' adaptation until it is sufficient to provide a survival advantage in the tumour microenvironmen”
BackgroundAlexandre, J., Nicco, C., Chéreau, C., Laurent, A., Weill, B., Goldwasser, F., & Batteux, F. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj049 · Cited by 199
Self-citationBahlis, N. J., Grad, J. M., Jordan-McMurry, I., Neil, J., Reis, I., Kharfan‐Dabaja, M. A., Eckman, J. R., Goodman, M. S., Fernandez, H. F., Boise, L., et al. (2002) · PubMed · Cited by 190
Maeda, H., Hori, S., Ohizumi, H., Segawa, T., Kakehi, Y., Ogawa, O., & Kakizuka, A. (2004) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401389 · Cited by 183
Role of p53 in Sensing Oxidative DNA Damage in Response to Reactive Oxygen Species-Generating Agents
Achanta, G., & Huang, P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0494 · Cited by 183 · cited 1×
“As a genome guardian, the p53 protein has a crucial role in sensing and removing oxidative damage to nuclear DNA and mtDNA, preventing oxidative gene mutations and genetic instabilit”
BackgroundSelf-citationJ.Kim, G., Chandrasekaran, K., & F.Morgan, W. (2006) · Mutagenesis · doi:10.1093/mutage/gel048 · Cited by 179 · cited 1×
“As cancer cells actively produce high levels of ROS and are consistently exposed to such endogenous oxidants, one would expect that the intrinsic oxidative stress may exert selective pressure to enrich the population of cells that are capable of stress adaptatio”
BackgroundCarew, J. S., Zhou, Y., Albitar, M., Carew, J. D., Keating, M. J., & Huang, P. (2003) · Leukemia · doi:10.1038/sj.leu.2403043 · Cited by 174 · cited 1×
“Besides oncogenic transformation, mitochondrial DNA (mtDNA) mutations have also been shown to be correlated with increased ROS levels in certain types of cancer cell, including those in solid tumours and leukaemi”
BackgroundSelf-citationRequirement for Rac1 in a K-ras–Induced Lung Cancer in the Mouse
Kissil, J. L., Walmsley, M. J., Hanlon, L., Haigis, K. M., Bender Kim, C. F., Sweet-Cordero, A., Eckman, M. S., Tuveson, D. A., Capobianco, A. J., Tybulewicz, V. L. J., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2300 · Cited by 167 · cited 1×
“This increase in ROS is required for the tumorigenic function of Ra”
BackgroundMotexafin gadolinium: A novel redox active drug for cancer therapy
Magda, D., & Miller, R. A. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.09.002 · Cited by 162
Juarez, J. C., Betancourt, O., Pirie-Shepherd, S. R., Guan, X., Price, M. L., Shaw, D. E., Mazar, A. P., & Doñate, F. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0171 · Cited by 162
The p53-induced Gene-6 (Proline Oxidase) Mediates Apoptosis through a Calcineurin-dependent Pathway
Rivera, A., & Maxwell, S. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504852200 · Cited by 160 · cited 1×
“Furthermore, p53 also acts as a transcription factor to regulate the expression of many pro-oxidant and antioxidant gene”
BackgroundMa, B., Goh, B. C., Tan, E. H., Lam, K. C., Soo, R., Leong, S. S., Wang, L. Z., Mo, F., Chan, A. T. C., Zee, B., et al. (2008) · Investigational New Drugs · doi:10.1007/s10637-007-9085-0 · Cited by 158
Fang, J., Sawa, T., Akaike, T., Greish, K., & Maeda, H. (2004) · International Journal of Cancer · doi:10.1002/ijc.11644 · Cited by 156
Xu, K., & Thornalley, P. J. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00526-8 · Cited by 149
Kopnin, P. B., Agapova, L. S., Kopnin, B. P., & Chumakov, P. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2466 · Cited by 146 · cited 1×
“Interestingly, besides the direct activation of ROS-producing enzymes, a recent study showed that Ras oncogenic signalling also suppresses the antioxidant molecule sestrin 1 ( SESN1”
BackgroundREDOX REGULATION BY INTRINSIC SPECIES AND EXTRINSIC NUTRIENTS IN NORMAL AND CANCER CELLS
McEligot, A. J., Yang, S., & Meyskens, Jr. (2005) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.25.050304.092633 · Cited by 144 · cited 1×
“Although the intrinsic mechanisms of increased oxidative stress in cancer cells have been studied extensively in recent year”
BackgroundKondoh, H., LLeonart, M. E., Bernard, D., & Gil, J. (2007) · PubMed · doi:10.14670/hh-22.85 · Cited by 143
Saydam, N., Kirb, A., Demir, Ö., Hazan, E., Oto, O., Saydam, O., & Güner, G. (1997) · Cancer Letters · doi:10.1016/s0304-3835(97)00245-0 · Cited by 141
Aberrant expression of selenoproteins in the progression of colorectal cancer
Murawaki, Y., Tsuchiya, H., Kanbe, T., Harada, K., Yashima, K., NOZAKA, K., TANIDA, O., 通盛, 河., Mukoyama, T., Nishimuki, E., et al. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.10.019 · Cited by 141
Thioredoxin and thioredoxin-binding protein-2 in cancer and metabolic syndrome
Ahsan, M. K., Nakamura, H., Masutani, H., & Yodoi, J. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.05.032 · Cited by 140 · cited 1×
“Another thiol-based antioxidant is the thioredoxin system, which seems to be upregulated in cancer cells and is correlated with cancer aggressiveness and drug resistanc”
BackgroundAntioxidant inhibitors for cancer therapy
Kong, Q., & Lillehei, K. O. (1998) · Medical Hypotheses · doi:10.1016/s0306-9877(98)90036-6 · Cited by 140 · cited 1×
“The idea of inducing preferential cancer cell death by a ROS-mediated mechanism based on the different redox states in normal and malignant cells ( Box 2 ) was proposed a decade ag”
BackgroundYoung, T. W., Mei, F. C., Yang, G., Thompson-Lanza, J. A., Liu, J., & Cheng, X. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0222 · Cited by 136 · cited 1×
“For example, oncogenic H - Ras -transformed cells, which exhibited increased superoxide and hydrogen peroxide levels, were shown to express higher levels of antioxidants such as peroxiredoxin-3 and thioredoxin peroxidase compared with their non-tumorigenic parental cell”
BackgroundKang, M. H., Wan, Z., Kang, Y. H., Sposto, R., & Reynolds, C. P. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn076 · Cited by 133 · cited 1×
“Interestingly, the combination of ABT-737 (an inhibitor of the pro-survival molecule BCL2) and 4HPR (which causes ROS-generation) was shown to enhance the mitochondrial apoptotic cascade with minimal cytotoxicity to normal lymphocyte”
BackgroundAntioxidant enzyme activities and the production of MDA and 8-oxo-dG in chronic lymphocytic lerkenia
Oltra, A. M., Carbonell, F., Tormos, C., Iradi, A., & Sáez, G. T. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00521-4 · Cited by 127
Tumor Intracellular Redox Status and Drug Resistance-Serendipity or a Causal Relationship?
Pervaiz, S., & Clement, M. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043384411 · Cited by 127 · cited 1×
“Under persistent intrinsic oxidative stress, many cancer cells become well-adapted to such stress and develop an enhanced, endogenous antioxidant capacity, which makes the malignant cells resistant to exogenous stres”
BackgroundANTIOXIDANT STATUS AND LIPID PEROXIDATION IN COLORECTAL CANCER
Skrzydlewska, E., Stankiewicz, A., Sulkowska, M., Sulkowski, S., & Kasacka, I. (2001) · Journal of Toxicology and Environmental Health, Part A · doi:10.1080/15287390152543690 · Cited by 126 · cited 1×
“Increases in ROS or oxidative DNA and lipid products in some primary cancer cells are associated with a decrease in antioxidants, such as SOD and catalas”
BackgroundKomatsu, D., Kato, M., Nakayama, J., Miyagawa, S., & Kamata, T. (2008) · Oncogene · doi:10.1038/onc.2008.102 · Cited by 119
Expression and Activity of NOX5 in the Circulating Malignant B Cells of Hairy Cell Leukemia
Kamiguti, A. S., Serrander, L., Lin, K., Harris, R. J., Cawley, J. C., Allsup, D. J., Slupsky, J. R., Krause, K.-H., & Zuzel, M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.12.8424 · Cited by 117
Lu, Y., Lou, Y. R., Yen, P., Newmark, H. L., Mirochnitchenko, O., Inouye, M., & Huang, M. (1997) · PubMed · Cited by 111
Experimental therapeutics: targeting the redox Achilles heel of cancer.
Cabello, C. M., Bair, W. B., & Wondrak, G. T. (2007) · PubMed · Cited by 110
Guzman, M. L., Li, X., Corbett, C. A., Rossi, R. M., Bushnell, T., Liesveld, J. L., Hébert, J., Young, F., & Jordan, C. T. (2007) · Blood · doi:10.1182/blood-2007-05-088815 · Cited by 107 · cited 1×
“A recent study showing that a compound known as TDZD-8 (4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione), can induce the depletion of thiols, leading to a rapid accumulation of ROS and selectively kill leukaemic cells expressing stem-cell markers with minimal toxicity to normal haemopoietic stem cell”
BackgroundRedox Regulation and Its Emerging Roles in Stem Cells and Stem-Like Cancer Cells
Ogasawara, M. A., & Zhang, H. (2008) · Antioxidants and Redox Signaling · doi:10.1089/ars.2008.2308 · Cited by 106 · cited 1×
“As cancer cells actively produce high levels of ROS and are consistently exposed to such endogenous oxidants, one would expect that the intrinsic oxidative stress may exert selective pressure to enrich the population of cells that are capable of stress adaptatio”
BackgroundNovel aspects of oxidative stress-associated carcinogenesis
Toyokuni, S. (2006) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.8.1373 · Cited by 104
Chemotherapy: induction of stress responses
Tiligada, E. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01272 · Cited by 103 · cited 1×
“Under persistent intrinsic oxidative stress, many cancer cells become well-adapted to such stress and develop an enhanced, endogenous antioxidant capacity, which makes the malignant cells resistant to exogenous stres”
BackgroundZhang, H., Trachootham, D., Lu, W., Carew, J. S., Giles, F. J., Keating, M. J., Arlinghaus, R. B., & Huang, P. (2008) · Leukemia · doi:10.1038/leu.2008.74 · Cited by 100
Self-citationProbing p53 biological functions through the use of genetically engineered mouse models
Attardi, L. D., & Donehower, L. A. (2005) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2004.08.022 · Cited by 97 · cited 1×
“Loss of functional p53 is associated with redox imbalance, increased ROS stress, high mutagenesis and aggressive tumour growt”
BackgroundPatel, B. P., Rawal, U. M., Dave, T. K., Rawal, R. M., Shukla, S. N., Shah, P. M., & Patel, P. S. (2007) · Integrative Cancer Therapies · doi:10.1177/1534735407309760 · Cited by 95 · cited 1×
“In solid tumours, studies have shown increased levels of oxidative damage products, such as oxidized DNA base (8OHdG), and lipid peroxidation products in clinical tumour specimens, plasma and cancer cell line”
BackgroundChemosensitization of Cancer by Nitric Oxide
Sullivan, R., & Graham, C. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208784246225 · Cited by 94 · cited 1×
“Under persistent intrinsic oxidative stress, many cancer cells become well-adapted to such stress and develop an enhanced, endogenous antioxidant capacity, which makes the malignant cells resistant to exogenous stres”
BackgroundDvořáková, K., Payne, C. M., Tome, M. E., Briehl, M. M., McClure, T. D., & Dorr, R. T. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00380-4 · Cited by 94 · cited 1×
“Through electrophile–nucleophile interactions, compounds such as isothiocyanates (benzyl isothiocyanate (BITC), phenethyl isothiocyanate (PEITC) and sulphoraphane) and aziridine derivatives (imexon) rapidly conjugate with GSH, causing a depletion of the GSH pool and subsequent oxidative stress and cell deat”
BackgroundCeccarelli, J., Delfino, L., Zappia, E., Castellani, P., Borghi, M., Ferrini, S., Tosetti, F., & Rubartelli, A. (2008) · International Journal of Cancer · doi:10.1002/ijc.23709 · Cited by 92 · cited 1×
“Another thiol-based antioxidant is the thioredoxin system, which seems to be upregulated in cancer cells and is correlated with cancer aggressiveness and drug resistanc”
BackgroundDestructive cycles: the role of genomic instability and adaptation in carcinogenesis
Schneider, B. L., & Kulesz-Martin, M. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh204 · Cited by 83
Models of reactive oxygen species in cancer
Lu, W., Ogasawara, M. A., & Huang, P. (2007) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2007.10.005 · Cited by 82 · cited 1×
“and experimental models to study intrinsic oxidative stress have been develope”
BackgroundSelf-citationLee, H., Cho, J., Shin, D., Yong, C. S., Choi, H.-G., Wakabayashi, N., & Kwak, M. (2008) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-008-9853-y · Cited by 82 · cited 1×
“Furthermore, recent work suggests that the transcription factor Nrf2 is responsible for resistance to the GSH-depleting agent BSO, and abrogation of Nrf2 in combination with BSO seemed to be an effective therapeutic strateg”
BackgroundKundu, N., Zhang, S., & Fulton, A. M. (1995) · Clinical & Experimental Metastasis · doi:10.1007/bf00144014 · Cited by 81 · cited 1×
“For example, tumour-associated macrophages were shown to induce sub-lethal oxidative stress in murine mammary tumour cells, possibly through the secretion of the inflammatory cytokine tumour necrosis factor-α ( TNF-α”
BackgroundAttia, S., Kolesar, J., Mahoney, M. R., Pitot, H. C., Laheru, D. A., Heun, J. M., Huang, W., Eickhoff, J. C., Erlichman, C., & Holen, K. D. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9123-6 · Cited by 81 · cited 1×
“, low clinical response and resistance to those agents were also reporte”
BackgroundInhibiting catalase activity sensitizes 36B10 rat glioma cells to oxidative stress
Smith, P. S., Zhao, W., Spitz, D. R., & Robbins, M. E. C. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.11.032 · Cited by 81 · cited 1×
“125 ); inhibitors of catalase and HMOX1 include 3-amino-1,2,4-triazol”
BackgroundTominaga, K., Kawahara, T., Sano, T., Toida, K., Kuwano, Y., Sasaki, H., Kawai, T., Teshima-Kondo, S., & Rokutan, K. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.08.029 · Cited by 78 · cited 1×
“Activity of ROS-generating enzymes in the NOX complex seems to increase in cancer cell lines and primary tissue”
BackgroundWondrak, G. T. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.03.035 · Cited by 73 · cited 1×
“These derivatives generate superoxide in the presence of molecular oxyge”
BackgroundThe role of p53 in base excision repair following genotoxic stress
Zurer, I. (2003) · Carcinogenesis · doi:10.1093/carcin/bgg186 · Cited by 72 · cited 1×
“As a genome guardian, the p53 protein has a crucial role in sensing and removing oxidative damage to nuclear DNA and mtDNA, preventing oxidative gene mutations and genetic instabilit”
BackgroundZhou, P., Kalakonda, N., & Comenzo, R. L. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05369.x · Cited by 68
Irmak-Yazicioglu, M. B., Ince-Dunn, G., Öztürk, M., & Çetin-Atalay, R. (2003) · PubMed · Cited by 65
Oxidant Stress and B Vitamins Status in Patients With Non-Small Cell Lung Cancer
Tsao, S.-M., Yin, M.-C., & Liu, W.-H. (2007) · Nutrition and Cancer · doi:10.1080/01635580701365043 · Cited by 62
Sensor/Effector Drug Design with Potential Relevance to Cancer
Fry, F. H., & Jacob, C. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206779010512 · Cited by 61 · cited 1×
“, but its feasibility has only recently gained momentu”
BackgroundChoi, J., Liu, R.-M., & Forman, H. J. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(96)00867-2 · Cited by 59
Antioxidants block proteasome inhibitor function in endometrial carcinoma cells
Llobet, D., Eritja, N., Encinas, M., Sorolla, A., Yeramian, A., Schoenenberger, J. A., Llombart-Cussac, A., Marti, R. M., Matias-Guiu, X., & Dolcet, X. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3282f24031 · Cited by 59
Rodrigues, M. S., Reddy, M. M., & Sattler, M. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2071 · Cited by 57
Phase I Trial of Imexon in Patients With Advanced Malignancy
Dragovich, T., Gordon, M., Mendelson, D., Wong, L., Modiano, M., Chow, H.-H. S., Samulitis, B., O'Day, S., Grenier, K., Hersh, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.9672 · Cited by 56
Cellular redox status regulates hypoxia inducible factor-1 activity. Role in tumour development.
Martínez-Sánchez, G., & Giuliani, A. (2007) · PubMed · Cited by 54
Linking stress-signaling, glutathione metabolism, signaling pathways and xenobiotic transporters
Yadav, S., Zając, E., Singhal, S. S., & Awasthi, S. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9043-5 · Cited by 48 · cited 1×
“Furthermore, the alterations in ROS-scavenging enzymes such as GSH also have a significant effect on the metabolism of alkylating agent”
BackgroundSmart Weapons Prove Tough to Design
Couzin, J. (2002) · Science · doi:10.1126/science.298.5593.522 · Cited by 46 · cited 1×
“However, current gene-targeting therapeutic strategies still face significant challenges owing to acquired drug resistance and the genomic instability of cancer cell”
Antioxidant potential in esophageal, stomach and colorectal cancers.
Skrzydlewska, E., Kozuszko, B., SULKOWSKA, M., Zalewski, B., Kozłowski, M., Snarska, J., Puchalski, Z., Sulkowski, S., & Skrzydlewski, Z. (2003) · PubMed · Cited by 40
Lenehan, P. F., Gutiérrez, P. L., Wagner, J. L., Milak, N., Fisher, G. R., & Ross, D. D. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050250 · Cited by 35 · cited 1×
“For example, multidrug resistant HL-60 leukaemia cells were shown to be resistant to the cytotoxic effect of H 2 O 2 ; this has mainly been attributed to elevated levels and activity of catalas”
BackgroundReactive Oxygen Species May Have Antitumor Activity in Metastatic Melanoma
Tuma, R. S. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm299 · Cited by 33 · cited 1×
“Elesclomol (STA-4783), a novel compound that showed therapeutic activity in malignant melanoma and prolonged the progression-free survival time in a Phase II clinical tria”
BackgroundVogel, A., Aslan, J. E., Willenbring, H., Klein, C., Finegold, M. J., Mount, H. T. J., Thomas, G., & Grompe, M. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.10.012 · Cited by 32 · cited 1×
“Although in certain cases apoptosis resistance can also be the result of post-translational event”
BackgroundHour, T., Huang, C., Lin, C.-C., Chen, J., Guan, J., Lee, J.-M., & Pu, Y. (2004) · Anti-Cancer Drugs · doi:10.1097/00001813-200409000-00007 · Cited by 30 · cited 1×
“Elevation of certain transcription factors, antioxidants and survival signals as a result of redox adaptation probably explains the drug-resistant phenotyp”
BackgroundRedox active disulfides: the thioredoxin system as a drug target.
Dl, K., Ehrmantraut, G., Stettner, S., Kunkel, M. W., & Powis, G. (1997) · PubMed · Cited by 30
The role of macrophage-derived TNFa in the induction of sublethal tumor cell DNA damage
Fulton, A. M., & Chong, Y. C. (1992) · Carcinogenesis · doi:10.1093/carcin/13.1.77 · Cited by 29
Free Radical Increases in Cancer: Evidence That There Is Not a Real Increase
Swartz, H. M., & Gutiérrez, P. L. (1977) · Science · doi:10.1126/science.201025 · Cited by 21
Gene expressions associated with chemosensitivity in human hepatoma cells.
Hoshida, Y., Moriyama, M., Otsuka, M., Kato, N., Taniguchi, H., Shiratori, Y., Seki, N., & Omata, M. (2007) · PubMed · Cited by 17
Drug approval triggers debate on future direction for cancer treatments
Frantz, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1972 · Cited by 9 · cited 1×
“However, current gene-targeting therapeutic strategies still face significant challenges owing to acquired drug resistance and the genomic instability of cancer cell”
BackgroundKim, H. J., Oridate, N., & Lotan, R. (2005) · PubMed · Cited by 3
Research works printed but not linked: 1
- Kim, G. J., Chandrasekaran, K. & Morgan, W. F. Mitochondrial dysfunction, persistently elevated levels of reactive oxygen species and radiation-induced genomic instability: a review. Mutagenesis 21, 361–367 (2006). · DOI · Paper page
Cited by
Ayala, A., Muñoz, M. F., & Argüelles, S. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/360438 · Cited by 6,349
Reactive oxygen species (ROS) as pleiotropic physiological signalling agents
Sies, H., & Jones, D. P. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0230-3 · Cited by 5,335
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
“In the absence of the redox maintenance pathway that is supported by these tumour suppressors, malignant cells might be selectively kille”
BackgroundReactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling
Ray, P. D., Huang, B.-W., & Tsuji, Y. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.01.008 · Cited by 4,373
Modulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579
Metadata
- Authors
- Trachootham, D., Alexandre, J., & Huang, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Huang, Peng
- Venue
- Nature Reviews Drug Discovery
- Published
- 2009-05-29
- Volume
- 8
- Issue
- 7
- Pages
- 579-591
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1972779889
- Cited by
- 5,452
- References
- 163
- Citations by year
- 2026: 322 · 2025: 332 · 2024: 340 · 2023: 372 · 2022: 421 · 2021: 462 · 2020: 444 · 2019: 454 · 2018: 393 · 2017: 404 · 2016: 341 · 2015: 289 · 2014: 282 · 2013: 204 · 2012: 158
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA085563, R01CA109041, CA109041, R01CA085563, R01CA100428, CA100428)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer and biochemical research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- reactive oxygen species, oxidative stress, redox modulation, cancer cells, drug resistance, antioxidant capacity, anticancer agents, genomic instability
- MeSH terms
- Adaptation, Physiological, Animals, Glutathione, Humans, Neoplasms, Oxidation-Reduction, Neoplastic Stem Cells, Reactive Oxygen Species, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.